Sponsor Directory

AbbVie clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

816

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Solid Tumor, Adult
Interventions: TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6, TTX-030 and budigalimab, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, TTX-030 and pembrolizumab, TTX-030, nab-paclitaxel and gemcitabine, Budigalimab and mFOLFOX6; Combination Product
Lead sponsor: Trishula Therapeutics, Inc.; Industry
Eligibility: 18 Years to 110 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 26
States / cities: Scottsdale, Arizona • Duarte, California • Los Angeles, California + 21 more

Conditions: Parkinson Disease
Interventions: Tavapadon, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 27
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Fountain Valley, California + 24 more

Conditions: Heavy Menstrual Bleeding, Uterine Fibroids
Interventions: Elagolix, Estradiol /norethindrone acetate (E2/NETA), E2/NETA Placebo, Elagolix Placebo; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 155
States / cities: Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 112 more

Conditions: Migraine
Interventions: Ubrogepant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 109
States / cities: Huntsville, Alabama • Saraland, Alabama • Little Rock, Arkansas + 92 more

Conditions: Refractory Follicular Lymphoma, Relapsed Follicular Lymphoma
Interventions: Ibrutinib, Venetoclax; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Hackensack, New Jersey • Seattle, Washington

Conditions: Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment
Interventions: Risankizumab, Comparator; Drug
Lead sponsor: AbbVie; Industry
Eligibility: Female only
Enrollment: 818 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 2
States / cities: Morrisville, North Carolina • Wilmington, North Carolina

Conditions: Irritable Bowel Syndrome
Interventions: 25mg Eluxadoline, 100mg Eluxadoline; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 6
States / cities: Corona, California • Miami, Florida • Stockbridge, Georgia + 2 more

Conditions: Alzheimer Disease
Interventions: ALIA-1758, Placebo; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Crohn's Disease
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 1,446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2030
U.S. locations: 45
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 36 more

Conditions: Myelofibrosis (MF)
Interventions: ABBV-744, Navitoclax, Ruxolitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 10
States / cities: Sacramento, California • Lebanon, New Hampshire • Buffalo, New York + 6 more

Conditions: HIV-1-infection, Elevated Cardiovascular Risk
Interventions: CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 45 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 19
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 14 more

Conditions: Ulcerative Colitis (UC)
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 8,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2028
U.S. locations: 169
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 131 more

About this AbbVie sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AbbVie is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AbbVie trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AbbVie clinical trials

Filter and sort this sponsor

Live official records

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Fixed-Dose Trial in Early Parkinson's Disease (PD)

Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications

A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)

A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants

A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

About this AbbVie sponsor directory page